54 results
424B5
LRMR
Larimar Therapeutics Inc
14 Feb 24
Prospectus supplement for primary offering
5:08pm
, unforeseen emergencies and other outbreaks of communicable diseases, including the ongoing COVID-19 pandemic and the efforts to mitigate
424B5
LRMR
Larimar Therapeutics Inc
13 Feb 24
Prospectus supplement for primary offering
4:46pm
health epidemics, unforeseen emergencies and other outbreaks of communicable diseases, including the ongoing COVID-19 pandemic and the efforts to mitigate
8-K
EX-99.2
9jkm7k8
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
qf9nykj
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
pcn 0iihzspc
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
424B5
d3bu6l
14 Sep 22
Prospectus supplement for primary offering
7:28am
8-K
EX-99.1
wjlls3cg4r
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
c2kfexr0nj0tz12uzl
14 Sep 22
Other Events
7:05am
8-K
EX-99.1
3tru8
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
y6x9zs mqx1vyty98rmz
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.1
bhwmym7fm807j3 33
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.2
xl1cy5 a6jxrku3
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.1
jkltvb2 ewvysoki6
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am